By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug Administration granted regular approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) for
December 6th 2023 / 12:15 PM PST By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 15, 2023, the U.S. Food and Drug Administration approved Repotrectinib (Augtyro) for adult patients with locally advanced
More
The Binaytara Foundation has proudly announced the 2023 Binaytara Career Advancement Awards recipients. The recipients of the 2023 awards attended Binaytara Foundation’s 2023 Annual Summit on Hematologic Cancers, Nashville, TN, and the
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 8, 2023, the U.S. Food and Drug Administration granted approval to Fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for adult patients who have metastatic colorectal cancer
More
By: BTF Staff October 28, 2023 – Known for its unwavering commitment to improving access to cancer care in resource-poor communities, the Binaytara Foundation hosted its “2023 Global Oncology Summit.” Central
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), significantly improves overall survival (OS) in renal cell carcinoma (RCC) patients at a higher risk of recurrence post- nephrectomy, according
More